US EditionA gene-editing method generates immunotherapeutic CAR T cells in the body
Azalea Therapeutics' dual-vector CRISPR system enables precise in vivo CAR T cell generation, achieving up to 40% CAR T cells in immune organs and clearing tumors in preclinical models.
8 Articles
8 Articles
A gene-editing method generates immunotherapeutic CAR T cells in the body
Laboratory-engineered immune cells called CAR T cells provide effective treatment for some cancers. Progress is being made towards creating these cells in vivo. Laboratory-engineered immune cells called CAR T cells provide effective treatment for some cancers. Progress is being made towards creating these cells in vivo.
New injectable system reprograms cancer-fighting T cells inside the body
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, quality-checked, shipped back, and then infused, all while the cancer continues. The process takes weeks. It costs between $400,000 and $500,000. Some patients don’t survive the wait. Many never get access at all. Scientists at UC San Francisco have no…
Now, a team of scientists from the University of California at San Francisco (UCSF) has developed a method for reprogramming these cells directly into the body. The breakthrough, published this week in Nature magazine, is the first time that a long sequence of DNA has been integrated into a specific human T-cell site without ever having been removed from the body. “I think this is just the beginning of a great wave of new therapies that will be …
In Vivo Precision Engineering to Reprogram T Cells
In a groundbreaking leap for cancer immunotherapy, researchers have successfully demonstrated the in vivo generation of chimeric antigen receptor (CAR) T cells through precise, site-specific genetic engineering directly within living hosts. This technological advance, recently detailed in a study published in Nature, represents a transformative shift from traditional ex vivo T cell manufacturing towards a […]
CAR-T cell therapy empowers the immune system to identify and attack cancer cells, but it requires immune cells to be created in a laboratory. However, a new method of genetic editing, tested in mice, allows the organism itself to generate them. The method was developed by a team headed by the University of California in San Francisco, USA, and has allowed the treatment of leukemia, multiple myeloma, and sarcoma in mice with the humanized immune…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
